Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical ...
ArriVent BioPharma is hosting a virtual investor event to discuss the firmonertinib clinical program, highlighting their commitment to transparency and engagement with stakeholders. Firmonertinib has ...
Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials. This is an ASCO Meeting Abstract from the 2023 ...
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical ...
16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results